Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICI) have become first-line treatment for metastatic colorectal cancer (CRC) with deficient mismatch repair (dMMR). Despite the remarkable response reported in preliminary trials, the role of ICI in patients with early-stage, operable CRC remains unclear. The aim of this study was to investigate trials on neoadjuvant ICI in operable CRC.

Materials and methods

Scoping review of clinical trial registries (Clinicaltrials.gov and EU clinical trial registers) and PubMed/Medline database of trials on neoadjuvant ICI for operable CRC was done up to December 2022.

Results

Some 40 trials investigating neoadjuvant ICI for early-stage, operable CRC were identified, including five published trials and three conference abstracts. Preclinica

SUBMITTER: Veen T 

PROVIDER: S-EPMC10491705 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature